Tag Archives: levodopa

Back to Basics: Why Basic Research (and the Fava Bean) are Key to the Cure

Do you hope for new treatments for PD? At the Parkinson’s Disease Foundation, we do. In fact, it’s the reason we exist. But how do we find them? And would you believe me if I told you the fava bean played an important role in the current gold-standard treatment for PD? When we think of finding better PD treatments, we often think of clinical trials — the final stage of research before PD drugs come to market. But there’s a crucial step at the very beginning of the pipeline that makes new drugs possible — basic science. Basic science looks… read more Read More

The Many Lives of Levodopa

The start of 2015 has been noteworthy for those with Parkinson’s disease (PD) as two new therapies  – Rytary™ and Duopa™ – were approved by the FDA at the start of January. Both therapies are updates to the gold-standard treatment of carbidopa/levodopa for those with PD. Manufacturers of both therapies hope to have the medications available on pharmacy shelves in the next few months. Yes, carbidopa/levodopa first came into use around 1970. However, these new therapies address a real need that current carbidopa/levodopa or Sinemet cannot meet … and that is good news. PDF has covered what Rytary and Duopa are (check out my… read more Read More

Why do Promising PD Treatments Fail?

On Tuesday, June 9th, the second day of the Movement Disorder Society International Congress in Paris, Dr. Warren Olanow, one of the world’s leading Parkinson’s specialists, gave a brilliant and authoritative talk on the subject of “What’s New in Parkinson’s Trials?” His focus was three high-profile clinical trials that have been watched intently and anxiously by people with Parkinson’s around the world. One was the Ceregene trial, in which a growth factor called neurturin (CERE-120) was delivered via a gene therapy technique. The second was STRIDE, in which a levodopa-COMT inhibitor (Stalevo(R)) was tested for its potential impact on improving… read more Read More